 Carcinoma, Renal Cell
"Carcinoma, Renal Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
| Descriptor ID |
D002292
|
| MeSH Number(s) |
C04.557.470.200.025.390 C04.588.945.947.535.160 C12.758.820.750.160 C12.777.419.473.160 C13.351.937.820.535.160 C13.351.968.419.473.160
|
| Concept/Terms |
Carcinoma, Renal Cell- Carcinoma, Renal Cell
- Carcinomas, Renal Cell
- Renal Cell Carcinomas
- Renal Cell Carcinoma
- Renal Cell Cancer
- Cancer, Renal Cell
- Cancers, Renal Cell
- Renal Cell Cancers
- Adenocarcinoma, Renal Cell
- Adenocarcinomas, Renal Cell
- Renal Cell Adenocarcinoma
- Renal Cell Adenocarcinomas
- Nephroid Carcinoma
- Carcinoma, Nephroid
- Carcinomas, Nephroid
- Nephroid Carcinomas
Clear Cell Renal Cell Carcinoma- Clear Cell Renal Cell Carcinoma
- Hypernephroma
- Hypernephromas
- Grawitz Tumor
- Tumor, Grawitz
- Carcinoma, Hypernephroid
- Carcinomas, Hypernephroid
- Hypernephroid Carcinoma
- Hypernephroid Carcinomas
- Clear Cell Renal Carcinoma
Collecting Duct Carcinoma (Kidney)- Collecting Duct Carcinoma (Kidney)
- Carcinoma, Collecting Duct (Kidney)
- Carcinomas, Collecting Duct (Kidney)
- Collecting Duct Carcinomas (Kidney)
- Duct Carcinoma, Collecting (Kidney)
- Duct Carcinomas, Collecting (Kidney)
- Collecting Duct Carcinoma of the Kidney
- Renal Collecting Duct Carcinoma
- Collecting Duct Carcinoma
- Carcinoma, Collecting Duct
- Carcinomas, Collecting Duct
- Collecting Duct Carcinomas
- Duct Carcinoma, Collecting
- Duct Carcinomas, Collecting
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Renal Cell".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Renal Cell".
This graph shows the total number of publications written about "Carcinoma, Renal Cell" by people in this website by year, and whether "Carcinoma, Renal Cell" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1985 | 0 | 1 | 1 | | 1986 | 2 | 1 | 3 | | 1989 | 1 | 0 | 1 | | 1990 | 1 | 0 | 1 | | 1991 | 1 | 0 | 1 | | 1992 | 3 | 0 | 3 | | 1993 | 1 | 0 | 1 | | 1994 | 2 | 0 | 2 | | 1995 | 2 | 0 | 2 | | 1996 | 1 | 2 | 3 | | 1997 | 1 | 0 | 1 | | 1998 | 5 | 0 | 5 | | 1999 | 3 | 0 | 3 | | 2000 | 8 | 0 | 8 | | 2001 | 3 | 3 | 6 | | 2002 | 8 | 0 | 8 | | 2003 | 6 | 1 | 7 | | 2004 | 13 | 1 | 14 | | 2005 | 10 | 3 | 13 | | 2006 | 18 | 2 | 20 | | 2007 | 11 | 1 | 12 | | 2008 | 17 | 0 | 17 | | 2009 | 11 | 0 | 11 | | 2010 | 11 | 2 | 13 | | 2011 | 6 | 1 | 7 | | 2012 | 4 | 1 | 5 | | 2013 | 9 | 2 | 11 | | 2014 | 13 | 2 | 15 | | 2015 | 10 | 1 | 11 | | 2016 | 16 | 0 | 16 | | 2017 | 7 | 1 | 8 | | 2018 | 11 | 1 | 12 | | 2019 | 11 | 0 | 11 | | 2020 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Carcinoma, Renal Cell" by people in Profiles.
-
Tjota M, Chen H, Parilla M, Wanjari P, Segal J, Antic T. Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous: Clinicopathologic and Molecular Study. Am J Surg Pathol. 2020 07; 44(7):943-954.
-
Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, Rishipathak D, Williams P, Kadel EE, Koeppen H, Chen YJ, Modrusan Z, Grogan JL, Banchereau R, Leng N, Thastrom A, Shen X, Hashimoto K, Tayama D, van der Heijden MS, Rosenberg JE, McDermott DF, Powles T, Hegde PS, Huseni MA, Mariathasan S. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nat Med. 2020 05; 26(5):693-698.
-
Gallan AJ, Antic T. Clinicopathologic Features of Small Renal Masses Associated With Distant Metastatic Disease. Am J Clin Pathol. 2020 04 15; 153(5):613-617.
-
Labadie BW, Liu P, Bao R, Crist M, Fernandes R, Ferreira L, Graupner S, Poklepovic AS, Duran I, Maleki Vareki S, Balar AV, Luke JJ. BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma. J Transl Med. 2019 11 25; 17(1):386.
-
Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA. Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer Discov. 2020 01; 10(1):40-53.
-
George DJ, Hessel C, Halabi S, Michaelson MD, Hahn O, Walsh M, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, Morris MJ, Choueiri TK. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. Oncologist. 2019 11; 24(11):1497-1501.
-
Parilla M, Alikhan M, Al-Kawaaz M, Patil S, Kadri S, Ritterhouse LL, Segal J, Fitzpatrick C, Antic T. Genetic Underpinnings of Renal Cell Carcinoma With Leiomyomatous Stroma. Am J Surg Pathol. 2019 08; 43(8):1135-1144.
-
Michaelson MD, Gupta S, Agarwal N, Szmulewitz R, Powles T, Pili R, Bruce JY, Vaishampayan U, Larkin J, Rosbrook B, Wang E, Murphy D, Wang P, Lechuga MJ, Valota O, Shepard DR. A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors. Oncologist. 2019 09; 24(9):1151-e817.
-
Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019 06 15; 393(10189):2404-2415.
-
Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DY, Lara PN, Choueiri TK, Maskens D, Singer EA, Eggener SE, Svatek RS, Stadler WM, Cole S, Signoretti S, Gupta RT, Michaelson MD, McDermott DF, Cella D, Wagner LI, Haas NB, Carducci MA, Harshman LC, Allaf ME. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol. 2019 May; 15(15):1683-1695.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|